搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
BioPharma Dive
7 天
Regeneron says study data support big bet on new blood thinners
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...
BioPharma Dive
6 天
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
BioPharma Dive
7 天
Novartis shutters MorphoSys sites, lays off staff
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down ...
BioPharma Dive
7 天
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
BioPharma Dive
8 天
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...
BioPharma Dive
13 天
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
BioPharma Dive
8 天
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...
BioPharma Dive
7 天
Ottimo raises $140M to compete in chase for new type of cancer drug
Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...
BioPharma Dive
9 天
Namandjé Bumpus, FDA’s No. 2 official, to depart agency at end of year
Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...
BioPharma Dive
9 天
Pfizer predicts stability, to Wall Street’s relief
The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...
BioPharma Dive
7 天
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...
BioPharma Dive
6 天
Ionis gets a milestone approval; Another top FDA official to step down
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈